Title
Category
Credits
Event date
Cost
$0.00
Click here to provide your feedback: https://activities.efficientcme.com/node/97/takecourse
  • AMA PRA Category 1 Credit™
$0.00
This module will focus on topics of debate in the MS arena including best practices in DMT switching, the impact of race and pregnancy on DMT choice, and the potential role of neurofilament light (NfL) in routine practice. 
  • AMA PRA Category 1 Credit™
$0.00
This module will focus on key clinical factors and practical considerations that may impact DMT initiation as well as utilization of the diverse agents available. Factors discussed include age, radiologic versus clinical disease activity, and usefulness of distinguishing between MS categories. It will shed light on how well long-held theories have withstood the test of time and help to provide deeper insight into how experts are approaching the contemporary management of MS.
$0.00
In November of 2019, Efficient conducted a survey of 56 community neurologists to assess current practice patterns and relative knowledge of new and emerging agents. Special focus was given to indications and use for novel abortive and preventive agents to capture in depth information regarding modern therapies and treatment strategies. Results demonstrate substantial educational gaps in diagnosis and management of this patient population. This needs assessment is divided into the following sections: 
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Attendance
$0.00
Overview:This case-based activity originally held as a satellite symposium in conjunction with MSVirtual2020 is designed to present several key analytic and diagnostic skills required to effectively characterize and treat neuromyelitis optica spectrum disorders (NMOSD). Presenting faculty work together through complex real-life cases that help to elucidate the major considerations and most common pitfalls in differentiating NMOSD from other neurodegenerative disorders such as multiple sclerosis.
$0.00
In January 2020, Efficient distributed a survey to ascertain current practice patterns and knowledge of neurologists that manage but do not subspecialize in the care of movement disorders. In particular, the survey was designed to evaluate neurologists’ approach to the assessment and management of patients with Parkinson’s disease (PD) experiencing “off episodes” as well as their use and/or knowledge of recently approved or late-stage investigational agents for this indication.
$0.00
Click here to provide your feedback: From Critique to Consensus: Course Evaluation | Efficient CME
  • AMA PRA Category 1 Credit™
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
  • AMA PRA Category 1 Credit™
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.
  • AMA PRA Category 1 Credit™
$0.00
Alzheimer's Disease (AD) is a unique condition in that it is widely researched with substantial representation in the literature, and yet still so much remains unknown or without consensus. With the field at a tipping point of biomarker and therapeutic developments, this activity attempts to provide neurologists, psychiatrists and other dementia clinicians with education that is both relevant and forward thinking.

Pages